BCG logo

BINAH CAPITAL GROUP INC

BCGNASDAQ
🏆 #4432 by market capEarnings Mar 29US Equity
$1.64▼ $0.17 (−9.39%)
Market closed · at close
🔔
Track BCG
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 9.4%
7d▲ 34.4%
14d▲ 48.4%
30d▲ 56.9%
ytd▼ 45.8%
1y▼ 25.5%
🏦Market Cap
$28M
Small Cap
📈Revenue Growth (YoY)
8.3%
Slowing
📊Gross Margin
19.5%
Thin
💵FCF Margin
2.6%
Thin
⚖️P/S Ratio
0.2x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.55 – $1.70
52-Week Range
$0.95 – $3.44
Volume (shares)
224,013
Avg Volume (shares)
—
Shares Outstanding
17.1M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$182M
Last Q Revenue
$51M
P/E Ratio
7.4
P/S Ratio
0.2x
EPS (TTM)
$0.25
Dividend Yield
4.06%
Dilution (1yr)
+1.3%
BCG logo

BINAH CAPITAL GROUP INC

BCG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$182M▲ +10.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
7.6%▲ +5.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$7M▲ +359.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5M▼ −825.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
16.8M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$16M▲ +$5M YoY
StockOtter · stockotter.space

About BINAH CAPITAL GROUP INC

Binah Capital Group, Inc. (BCG), along with its associated companies, is active in the wealth management sector. The firm furnishes financial advisors with comprehensive execution capabilities for a broad spectrum of investments, including equities, fixed-income securities, exchange-traded funds (ETFs), and options. Furthermore, it supplies essential support services to these advisors, encompassing research, regulatory compliance, supervisory guidance, and accounting. BCG's product portfolio also features mutual funds and various insurance solutions, in addition to specialized alternative investments like non-traded real estate investment trusts (REITs), unit trusts, and both fixed and variable annuities. Established in 2016, Binah Capital Group maintains its corporate headquarters in Albany, New York, and operates as a subsidiary of MHC Securities, LLC.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·9d ago

Binah Capital Group Reports Results for Third Quarter of 2026

- Assets Under Management (“AuM”) Increased 5.0% Year-over-Year to $31.4 Billion -

Business Wire·11d ago

enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the pivotal Cohort 1 of

GuruFocus·29d ago

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu

GuruFocus·29d ago

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi

GuruFocus·Oct 22

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv

Business Wire·Oct 14

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for